Release patterns of 5-aminosalicylic acid in human small intestine: Importance of galenic preparation;Bedeutung der galenik fur die luminale freisetzung von 5- aminosalicylsaure im menschlichen dunndarmlumen

Medizinische Klinik

Volumn 93, Issue 5, 1998, Pages 294-299

  Keller, Jutta ^a   Goebell, Harald ^b   Klotz, Ulrich ^c   Layer, Peter ^a  

^a ISRAELITISCHES KRANKENHAUS   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

5 Aminosalicylic acid (5 ASA); Excretion; Interdigestive, postprandial; Intraluminal release

Indexed keywords

EUDRAGIT; MESALAZINE;

ADULT; ARTICLE; DRUG EFFICACY; DUODENUM MUCOSA; HUMAN; HUMAN EXPERIMENT; INTESTINE SECRETION; MANOMETRY; NORMAL HUMAN; POSTPRANDIAL STATE; SMALL INTESTINE; SMALL INTESTINE DISEASE; SOLUBILIZATION; STOMACH EMPTYING; URINARY EXCRETION; BIOAVAILABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; ENTERIC COATED TABLET; METABOLISM;

BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; HUMANS; INTESTINE, SMALL; MESALAMINE; TABLETS, ENTERIC-COATED;

EID: 0032523332     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044864     Document Type: Article

References (38)

1. Allgayer H, Ahrifelt NO, Kruis W, et al. Colonic N-acetylation of 5-aminosalcylic acid in plasma and urine Gastroenterology 1989;97 38-41.
2. Azad Khan AK, Pins J, Truelove SC An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;1:892-5.
3. Azad Khan AK, Truelove SC, Aronson R. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Pharmacol 1982;3:523.
4. Bachrach WH. Sulphasalazine. An historical perspective. Am J Gastroenterol 1988;83:487-96.
5. Barve S, Joshi-Barve S, Talwalker R, Mc Clain CJ, Varilek GW. Mesalamine (5-ASA) and the anti-oxidant, vitamin E inhibit interleukin-1 (II-1) mediated activation of nuclear factor (B (NF(B) in CACO-2 cells. Gastroenterology 1995;108:A777.
6. Bayless TM, Maintenance therapy for Crohn's disease. Castroenterology 1996;110:299-302.
7. Brynskov J, Norby Rasmussen S. Clinical pharmacology: Development of new forms of treatment of inflammatory bowel disease. Scand J Gastroenterol 1996;31:Suppl 216:175-80.
8. Christensen LA, Fallingborg J, Jacobsen BA, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 1994;8:289-94.
9. Christensen LA, Fallingborg J, Jacobsen BA, Rasmussen SN. Pharmakokinetik der oral verabreichten 5-Aminosalizylsäure (Mesalazin)-Präparate; Unterschiede und mögliche klinische Auswirkungen. Chir Gastroenterol 1993,9:Supp 1 1:38-43
10. De Mey C, Meineke I. Prandial and diurnal effects on the absrption of orally administered enteric coated 5-amino-salicylic acid (5-ASA) Br J Clin 1992;33 179-102.
11. Ewe K, Press AG, Oestreicher XX. Einfluß der Nahrungsaufnahme auf die Magenentleerung magensaftresistenter Tabletten und Kapseln. Dtsch Med Wochenschr 1992;117:287-90.
12. Fischer C, Maier K, Klotz U, Simplified high performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr 1981;225: 498-503
13. Goebell H, Klotz U, Nehlsen B, Layer P. Oro-ileal transit of slow release 5-aminosalicylic acid. Gut 1993;34: 669-75.
14. Greenfield SM, Punchard NA, Teare JP, Thompson RPH. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993;7:369-83.
15. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334:841-8.
16. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for the treatment of active ulcerative colitis. Result of a controlled trial. Am J Gastroenterol 1993;88:1188-97.
17. Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy J Clin Pharmacol 1993;33:712-8
18. Klotz U, Maier KE, Fischer C, Bauer KH. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneim Forsch 1985;35:636-9
19. Larouche J, Morais J, Picard M, et al Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment Pharmacol Ther 1995;9:315-20.
20. Lauritsen K, Hansen J, Bytzer P, Bukhave K, Rask-Madsen J. Effects of sulphasalazine and disodium azodisalicylate on colonie PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 1984,25:1271-8.
21. Layer PH, Goebell H, Keller J, Dignass A, Klotz U. Delivery and fate of oral mesalanune microgranules within the human small intestine Gastroenterology 1995;108: 1427-33.
22. Liu ZC, McClelland RA, Uetrecht JP. Oxidation of 5-aminosalicylic acid by hypochlorus acid to a reactive iminoquinone Drug Metab Dispos 1995;23:246-50
23. MacDermotr RP, Schloemann SR, Bertovich MJ, et al. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology 1989;96:442-8.
24. McLeod RS, Wolff BG, Steinhart AH, et al Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Castroenterology 1995;109 404-13.
25. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995;40:296-304
26. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987;28:190-5.
27. Modigliani R, Colombel JF, Dupas J-L, et al. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance. Gastroenterology 1996;110:688-93.
28. Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987;28:196-200.
29. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I. Inibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulphasalazine and 5-amunosalicylic acid. Dig Dis Sci 1987;32:577-82.
30. Ouyang A, Sunshine AG, Reynolds JC. Caloric content of a meal affects duration but not contractile pattern of duodenal motility in man. Dig Dis Sci 1989;34:528-36.
31. Peppercorn MA. A critical evaluation of the therapeutic benefits and side effects of aminosalicylate analogues in the treatment of inflammatory bowel disease. Inflammopharmacology 1993;2:263-76.
32. Rasmussen SN, Bondesen S, Huidberg EF, et al. 5-aminosalicylic acid in a slow release preparation: biovailability, plasma level and excretion in humans. Gastroenterology 1982;83:1062-70.
33. Rijk MCM, van Schaik A, van Tongeren JHM. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol 1988;23: 107-12.
34. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 1994;8:27-34.
35. Singleton JW, Hanauer SB, Gitnick GL, et al. and the Pentasa Crohn's Disease Study Group. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16 week trial. Gastroenterology 1993;104:1293-301.
36. Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells J Pharmacol Exp Ther 1995;272:399-406.
37. Weisbrodt NW Motility of the small intestine. In: Johnson RJ, Christensen J, Jackson MJ, Jacobson BD, Walsh JH, eds. Physiology of the gastrointestinal tract, 2nd edn. Vol 1. New York: Raven Press, 1987:631-63.
38. Yu DK, Elvin AT, Morrill B et al. Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. Clin Pharmacol Ther 1990;48:26-33.